As Filed with the Securities and Exchange Commission on January 10, 2024


Registration No. 333-________





Washington, D.C. 20549












(Exact name of registrant as specified in its charter)


FLORIDA   59-3410522

(State or other jurisdiction of

incorporation or organization


(I.R.S. Employer

Identification No.)


4902 Eisenhower Boulevard, Suite 125

Tampa, Florida 33634



(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)





(Full Title of the Plans)



Kimberly Murphy,

Chief Executive Officer.

4902 Eisenhower Boulevard, Suite 125

Tampa, Florida 33634


(Name, Address and Telephone number of Agent for Service)


Copies to:



Mark A. Catchur, Esquire

Shumaker, Loop & Kendrick, LLP

101 E. Kennedy Blvd., Suite 2800

Tampa, Florida 33602

(813) 229-7600


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐











This Registration Statement on Form S-8 of Oragenics, Inc. (the “Company”) is being filed to register 1,000,000 additional shares of Company common stock authorized for issuance under the 2021 Equity Incentive Plan (the “2021 Plan”) (which is an amendment and restatement of the Company’s 2012 Equity Incentive Plan), pursuant to General Instruction E to Form S-8. The table below summarizes the Plan, as amended to date and the registration statements previously filed to cover shares authorized for issuance under the Plan.


Summary Plan Table



Plan History













2021 Equity Incentive Plan  February 2022   10,000,000*   166,667   333-263821
First Amendment to 2021 Plan  December 2023   1,000,000    1,166,667    



*On January 20, 2023, the Company effected a 1 for 60 reverse stock split and the amounts reflected prior to the January 2023 reverse split have been adjusted for such reverse split. On December 14, 2023, the Company’s shareholders approved an increase in the number of authorized shares for issuance under the Plan from 166,667 shares to 1,166,667 shares or an additional 1,000,000 shares. This Registration Statement registers the additional 1,000,000 shares approved by the Company’s shareholders.


Pursuant to General Instruction E to Form S-8, the contents of the previously filed Registration Statement, on Form S-8 (No. 333-263821), on March 24, 2022 is incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.









The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).






Item 3. Incorporation of Documents by Reference.


This Registration Statement on Form S-8 incorporates by reference the following documents we previously filed with the Securities and Exchange Commission:


  Registration Statement on Form S-8 filed March 24, 2022 (File No. 333-263821);
  the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on April 17, 2023;
  the Registrant’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, filed with the Commission on May 12, 2023, August 11, 2023 and November 9, 2023; and
  the Registrant’s Current Reports on Form 8-K, filed with the Commission on each of January 23, 2023, February 3, 2023, February 24, 2023, March 1, 2023, March 8, 2023, March 14, 2023, April 3, 2023, April 10, 2023, June 5, 2023, August 7, 2023, August 10, 2023, August 18, 2023, September 15, 2023, September 29, 2023, October 5, 2023, October 5, 2023, November 2, 2023, November 20, 2023, December 8, 2023, December 15, 2023, December 29, 2023 and January 2, 2024.


All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents. In no event, however, will any information that the Registrant discloses under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form 8-K that the Registrant may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration Statement. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or amended, to constitute a part of the Registration Statement.


Item 8. Exhibits.


See the Exhibit Index immediately following the signature page which is incorporated herein by reference.







Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tampa, State of Florida this 10th day of January, 2024.


  Oragenics, Inc.
  By: /s/ Kimberly Murphy
    Kimberly Murphy

Chief Executive Officer and

Principal Executive Officer




Each of the undersigned officers and directors of Oragenics, Inc., hereby constitutes and appoints Kimberly Murphy and Janet Huffman, each their true and lawful attorneys-in-fact and agents, for them and in their name, place and stead, in any and all capacities, to sign their names to any and all amendments to this Registration Statement on Form S-8, including post-effective amendments and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.


Pursuant to the requirements of the Securities Act of 1933, this S-8 Registration Statement has been signed by the following persons in the capacities and on the dates indicated.


Signature   Title   Date

/s/ Kimberly Murphy

  Chief Executive Officer, Principal Executive   January 10, 2024
Kimberly Murphy   Officer and Director    

/s/ Janet Huffman

  Chief Financial Officer and Principal   January 10, 2024
Janet Huffman   Accounting Officer    

/s/ Charles Pope

  Chairman of the Board and Director   January 10, 2024
Charles L. Pope        

/s/ Frederick W. Telling

  Director   January 10, 2024
Frederick W. Telling        

/s/ Robert C. Koski

  Director   January 10, 2024
Robert C. Koski        

/s/ Alan W. Dunton

  Director   January 10, 2024
Alan W. Dunton        

/s/ John Gandolfo

  Director   January 10, 2024
John Gandolfo        

/s/ Bruce Cassidy

  Director   January 10, 2024
Bruce Cassidy        









  Exhibit Description
4.1   2021 Equity Incentive Plan (incorporated by reference as Exhibit 10.1 to Form 8-K filed on February 28, 2022).
4.2   First Amendment to Equity Incentive Plan (incorporated by reference to Exhibit 4.2 to Form 8-K filed on December 15, 2023)
4.3   Amended and Restated Warrant Form (incorporated by reference as Exhibit 4.1 to Form 8-K filed on August 1, 2017).
4.4   Form of Common Stock Warrant (incorporated by reference as Exhibit 4.1 to Form 8-K filed on November 9, 2017).
4.5   Form of Warrant to purchase shares of Common Stock (incorporated by reference as Exhibit 4.2 to Form S-1/A filed on July 9, 2018).
4.6   Warrant Agency Agreement (incorporated by reference as Exhibit 4.2 to Form 8-K filed on July 17, 2018).
4.7   Form of Series 2 Warrant (incorporated by reference as Exhibit 4.2 to Form 8-K filed on March 25, 2019).
4.8   Warrant dated May 1, 2020 (incorporated by reference as Exhibit 4.1 to Form 8-K filed on May 4, 2020).
4.9   Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference as Exhibit 4.9 to Form 10-K filed on April 17, 2023).
5.1   Opinion of Shumaker, Loop & Kendrick, LLP, as to the legality of the securities being registered.
23.1   Consent of Independent Registered Public Accounting Firm, Mayer Hoffman McCann P.C.
23.2   Consent of Shumaker, Loop & Kendrick, LLP to the use of their opinion as an Exhibit to this Registration Statement is included in their opinion filed herewith as Exhibit 5.1.
24.1   Power of Attorney (included with the signature page to this Registration Statement).
107   Filing Fee Table.